MWM
VRTX icon

Massachusetts Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Massachusetts Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$283K Sell
634
-88
-12% -$41K 0.12% 90
2025
Q4 		$327K Hold
722
– – 0.15% 84
2025
Q3 		$283K Buy
722
+162
+29% +$67.7K 0.14% 87
2025
Q2 		$249K Sell
560
-37
-6% -$17.1K 0.14% 90
2025
Q1 		$289K Buy
+597
New +$278K 0.2% 76

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Wealth Management's VRTX Position: Q1 2026 in Review

Massachusetts Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 12% in Q1 2026, selling an estimated $41K and leaving 634 shares worth $283K. The position accounts for 0.12% of the portfolio, ranked #90.

Massachusetts Wealth Management first reported a position in VRTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $327K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Massachusetts Wealth Management held 634 shares of Vertex Pharmaceuticals worth $283K as of Q1 2026.
  • Massachusetts Wealth Management sold 88 Vertex Pharmaceuticals shares in Q1 2026, an estimated $41K.
  • Vertex Pharmaceuticals made up 0.12% of Massachusetts Wealth Management's portfolio in Q1 2026, its #90 holding.
  • Massachusetts Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Massachusetts Wealth Management's Vertex Pharmaceuticals position peaked at $327K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Massachusetts Wealth Management's 13F filing for Q1 2026, filed 15 Apr 2026.